Nina Wagner-Johnston

Associate Professor


Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output


Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

Hamlin, P. A., Flinn, I. W., Wagner-Johnston, N., Burger, J. A., Coffey, G. P., Conley, P. B., Michelson, G., Leeds, J. M., Der, K., Kim, Y., Sabalvaro-Torres, A., Birrell, M., Pandey, A., Curnutte, J. T. & Patel, M. R., Apr 2019, In : American journal of hematology. 94, 4, p. E90-E93

Research output: Contribution to journalLetter


Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

Salles, G., Schuster, S. J., De Vos, S., Wagner-Johnston, N. D., Viardot, A., Blum, K. A., Flowers, C. R., Jurczak, W. J., Flinn, I. W., Kahl, B. S., Martin, P., Kim, Y., Shreay, S., Will, M., Sorensen, B., Breuleux, M., Zinzani, P. L. & Gopal, A. K., Mar 31 2017, In : Haematologica. 102, 4, p. e156-e159

Research output: Contribution to journalLetter


Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria

Rashidi, A., Oak, E., Carson, K. R., Wagner-Johnston, N. D., Kreisel, F. & Bartlett, N. L., May 3 2016, In : Leukemia and Lymphoma. 57, 5, p. 1191-1193 3 p.

Research output: Contribution to journalLetter


Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

Wagner-Johnston, N. D., Bartlett, N. L., Cashen, A. & Berger, J. R., Nov 1 2012, In : Leukemia and Lymphoma. 53, 11, p. 2283-2286 4 p.

Research output: Contribution to journalLetter